Since heart‐specific PGC‐1α overexpression exhibits dilated myopathy in mice (Lehman et al., 2000), this plausible adverse effect in the heart should be considered when developing therapeutic agents targeting PGC‐1α. Here, PPARGC1A is linked to Vascular dilatation.